Sanofi's net income 2007-2019

In 2019, Sanofi’s net income amounted to some 2.8 billion U.S. dollars. Over the past eleven years, the French pharmaceutical company’s net income numbers have fluctuated significantly.

Assets and revenue

Sanofi S.A. had a total assets value of over 112 billion U.S. dollars in 2019, which is the highest asset value the company has had over the past decade. In the same year, the pharmaceutical giant generated over 36 billion U.S. dollars’ worth of revenue. Thus, Sanofi’s 2019 revenue numbers were the highest in the last decade.

Sanofi’s pharmaceutical products

Sanofi produces a variety of pharmaceutical drugs and products, such as Lantus, Plavix, and Fabrazyme, to name a few. Generating roughly three billion U.S. dollars in 2019, the company’s top product was Lantus (insulin glargine). With some 190 products in the pipeline, Sanofi spent approximately 6 billion U.S. dollars on research and development in 2019. The company’s R&D expenditures have been increasing steadily since 2013.